Inhibikase Therapeutics (IKT) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Inhibikase Therapeutics (IKT) is Neutral.

The composite score behind that read is +0.08, weighing +0.38 of bullish evidence against -0.25 bearish.

Inhibikase Therapeutics last closed at $1.97, +3.14% on the session.

Against the IVW growth benchmark the position is +2.34% over the forecast window.

The read is built from 15 underlying insights — 6 bullish and 9 bearish.

Agreement across those insights is 60%.

11 graded predictions for IKT so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Inhibikase Therapeutics in the 20th percentile on return on equity, where 100 is best.

Inhibikase Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $266.51M.

StockMap tracks Inhibikase Therapeutics as the 220th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Inhibikase Therapeutics ranks 51st of 381 in the group, against a group median of -0.08.